dr. Renate De Smedt (PhD)

CRIG member
Renate De Smedt


Postdoctoral researcher - Lab Normal and Malignant Hematopoiesis, Center for Medical Genetics (Faculty of Medicine and Health Sciences, UGent)
Principal Investigator: prof. Pieter Van Vlierberghe (PhD) 

 

Research focus

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer that is currently treated with intensive chemotherapy. These treatments come with long-term harmful side-effects – particularly in children – including infertility, reduced intellectual capacity and the development of secondary tumors. Although prognosis has improved with combination therapy, a significant number of T-ALL patients relapse and become refractory to treatment, indicating the need for improved and targeted therapy. Therefore, our research group investigates the molecular basis of childhood leukemia and the interaction between tumor cells, chemotherapeutics and the tumor microenvironment, to identify novel therapeutic targets that could result in the development of less toxic and more effective drugs for treatment of childhood leukemia.
 

Key publications

  • ‘Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma’. Blood, 2020. (PMID: 32315407)
  • ‘Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma’. Haematologica, 2019. (PMID: 30076176)
  • ‘Targeting steroid resistance in T-cell acute lymphoblastic leukemia’. Blood Reviews, 2019. (PMID: 31353059)
     

Contact & links

  • Lab address: Ghent University, Center for Medical Genetics Ghent, Lab of Normal and Malignant Hematopoiesis, Medical Research Building 2 (entrance 38), 1st Floor, Room 110.007, Corneel Heymanslaan 10, 9000 Ghent, Belgium
  • Center for Medical Genetics  
  • Renate De Smedt is interested to receive invitations for presentations or talks